SmallCapReview.com is a leading small cap stock information site since 1999, to register for the free SmallCapReview newsletter visit http://www.smallcapreview.com.
The Medicines Company (Nasdaq: MDCO) $7.57. Today announced the publication of one-year results from the landmark HORIZONS-AMI Trial. The trial showed that patients who had suffered the most severe form of heart attack and received angioplasty were significantly less likely to suffer cardiac death and had significantly better overall survival if treated with Angiomax� (bivalirudin) compared with those treated with heparin plus a platelet glycoprotein IIb/IIIa inhibitor (GPI).
The data, published in the August 30 issue of The Lancet, followed more than 3,000 patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).
What They Do: HORIZONS-AMI, co-funded by a grant from The Medicines Company, is the largest study to focus on the appropriate use of anticoagulation medications and stents in patients experiencing STEMI and undergoing primary percutaneous coronary intervention (PCI), commonly known as angioplasty.
Cytokinetics, Incorporated (Nasdaq: CYTK) $3.04. Today announced that data from two Phase IIa clinical trials evaluating omecamtiv mecarbil (formerly CK-1827452), one in stable heart failure patients and one in patients with ischemic cardiomyopathy and angina, were presented at the European Society of Cardiology Congress 2009 in Barcelona, Spain. The company believes these data provide support for the further clinical development of this novel drug candidate as a potential treatment for heart failure. Amgen Inc. exercised an option to obtain an exclusive, world-wide (excluding Japan) license to omecamtiv mecarbil, subject to specified development and commercialization participation rights of Cytokinetics.
What They Do: Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.
Citadel Investment Group LLC, Today announced that it has terminated a plan to sell up to 120 million shares of E-Trade Financial Corp. (Nasdaq: ETFC) $1.64. The plan was due to start on Monday. "Citadel believes that the termination of the plan at this time is in the best interests of E-Trade and all of its stakeholders," said Citadel in a statement. "Ken Griffin, Citadel founder and chief executive, has consulted with E-Trade's board of directors and they have been fully apprised of Citadel's decision." E-Trade's stock was the biggest gainer in the S&P 500 Index on Friday, up 13%. On Wednesday, Standard & Poor's Ratings Services raised E-Trade's ratings because of a recent debt exchange.
What They Do: E*TRADE Financial Corporation, through its subsidiaries, provides online brokerage and related products and services primarily to individual retail investors, under the brand name of E*TRADE Financial worldwide.
IncrediMail Ltd. (Nasdaq: MAIL) $10.03. Today announced that its Board of Directors approved an interim cash dividend of $3.8 million, which is approximately $0.40 per share. Distributing the dividend is subject to receipt by the Company of a tax pre-ruling from the Israeli Tax Authority as required by Israeli law.
This interim dividend is equivalent to the Company's net earnings in the first half of 2009, and is part of the Company's dividend policy, as announced on March 12, 2009, whereby at least 50% of the Company's annual net income is planned to be paid out as a dividend.
What They Do: IncrediMail Ltd. is an internet company that develops customized, downloadable graphic consumer applications used to generate search related revenues and designs, markets and delivers high end personal desktop software.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com has been a leading site for news on small-cap stocks since 1999. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select small-cap stocks, to register visit http://www.smallcapreview.com/.
